Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.

In the visual abstract, the colors of the Intermediate and Adverse curves were inverted in the Leukemia-free survival and Overall survival graphs. The corrected visual abstract is shown below:

The publisher apologizes for the errors, which have been corrected in the published article.